Recent Security Class Actions

Y-mAbs Therapeutics Inc. Common Stock (NASDAQ: YMAB)

48 Days left to seek lead plaintiff status.

Company Name:Y-mAbs Therapeutics Inc. Common Stock
Stock Symbol:NASDAQ: YMAB
Class Period Start:10/06/2020
Class Period End (inclusive):10/28/2022
Filing Deadline:03/19/2023

The Complaint alleges that throughout the Class Period, Y-mAbs misrepresented to investors that, pursuant to a series of meetings and other communications between Y-mAbs and the FDA, that progress was being made that would align with the FDA's requirement to demonstrate substantial evidence of effectiveness, sufficient for approval of omburtamab. The Complaint further alleges that Y-mAbs failed to advise investors that it had elected to submit the March 31, 2022 Biologics License Application prior to reaching agreement with the FDA on the content of the application and that the true facts were first disclosed to investors shortly after the opening of trading on October 26, 2022 when the FDA published its Briefing Document for an October 28, 2022 Advisory Committee (“AdCom”) Meeting, and again, on October 28, 2022 when the AdCom vote 16-0 against recommending approval of omburtamab.

Y-mAbs Therapeutics Inc. Common Stock (NASDAQ: YMAB) Claim Form

Name(Required)
Address
Consent(Required)
This field is for validation purposes and should be left unchanged.